United Therapeutics (NASDAQ:UTHR) CEO Martine Rothblatt Sells 9,500 Shares

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of the stock in a transaction that occurred on Wednesday, June 3rd. The shares were sold at an average price of $547.61, for a total value of $5,202,295.00. Following the completion of the sale, the chief executive officer directly owned 40,513 shares of the company’s stock, valued at approximately $22,185,323.93. This represents a 19.00% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

United Therapeutics Trading Down 0.3%

NASDAQ UTHR traded down $1.78 on Thursday, reaching $547.69. 388,825 shares of the company were exchanged, compared to its average volume of 478,978. The business’s fifty day moving average price is $567.74 and its 200 day moving average price is $518.04. The stock has a market capitalization of $23.25 billion, a P/E ratio of 20.22, a price-to-earnings-growth ratio of 1.75 and a beta of 0.57. United Therapeutics Corporation has a fifty-two week low of $272.12 and a fifty-two week high of $609.35.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). The company had revenue of $781.50 million for the quarter, compared to analyst estimates of $797.40 million. United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The business’s quarterly revenue was down 1.6% on a year-over-year basis. During the same period last year, the firm posted $6.63 EPS. Equities research analysts forecast that United Therapeutics Corporation will post 26.92 earnings per share for the current year.

Analyst Upgrades and Downgrades

UTHR has been the topic of a number of recent research reports. HC Wainwright boosted their price objective on United Therapeutics from $600.00 to $660.00 and gave the stock a “buy” rating in a research note on Tuesday, March 31st. TD Cowen reissued a “buy” rating on shares of United Therapeutics in a research note on Thursday, May 21st. Bank of America boosted their price objective on United Therapeutics from $569.00 to $626.00 and gave the stock a “neutral” rating in a research note on Tuesday, March 31st. Royal Bank Of Canada lowered their price objective on United Therapeutics from $707.00 to $701.00 and set an “outperform” rating on the stock in a research note on Thursday, May 7th. Finally, Wells Fargo & Company raised United Therapeutics from an “equal weight” rating to an “overweight” rating and boosted their price objective for the stock from $575.00 to $735.00 in a research note on Thursday, May 7th. Eleven investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, United Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $619.42.

Hedge Funds Weigh In On United Therapeutics

Several large investors have recently modified their holdings of UTHR. Geneos Wealth Management Inc. lifted its stake in shares of United Therapeutics by 141.7% in the 1st quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company’s stock valued at $45,000 after purchasing an additional 85 shares during the last quarter. Northwestern Mutual Wealth Management Co. lifted its stake in shares of United Therapeutics by 18.8% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 443 shares of the biotechnology company’s stock valued at $127,000 after purchasing an additional 70 shares during the last quarter. Jump Financial LLC acquired a new position in shares of United Therapeutics in the 2nd quarter valued at $277,000. Cerity Partners LLC lifted its stake in shares of United Therapeutics by 77.3% in the 2nd quarter. Cerity Partners LLC now owns 12,843 shares of the biotechnology company’s stock valued at $3,691,000 after purchasing an additional 5,600 shares during the last quarter. Finally, Bank of Nova Scotia raised its holdings in shares of United Therapeutics by 6.9% in the 2nd quarter. Bank of Nova Scotia now owns 1,628 shares of the biotechnology company’s stock valued at $468,000 after buying an additional 105 shares during the period. Institutional investors and hedge funds own 94.08% of the company’s stock.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.